Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer
Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer
Immutep的Efti与MSD的KEYTRUDA在一线头颈癌中表现出良好的安全性和疗效
- Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024
- In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR (34.5% ORR including partial response after data cut-off) versus 18.5% ORR for KEYTRUDA
- Efti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any PD-L1 expression and combination continues to have favourable safety profile
- Statistically significant increase in absolute lymphocyte count biomarker seen in the efti in combination with KEYTRUDA arm shows efti's biological activity in a randomised setting
- Based on the high unmet need and encouraging results to date, with Overall Survival expected in 2025, the path forward will be discussed with regulatory agencies
- 在2024年的ESMO大会上，在备受关注的提供论文口头报告中发布了结果。
- 在具有任何PD-L1表达（CPS≥1）的患者中，efti与KEYTRUDA的组合表现最佳，CPS≥20的ORR为31.0%（包括截止数据后的部分反应，ORR达到34.5%），而KEYTRUDA的ORR为18.5%。
- 在任何PD-L1表达患者中，efti与KEYTRUDA的联合治疗导致了高达17.5个月的持续反应，并且联合治疗的安全性持续良好。
- 在随机设定中，efti与KEYTRUDA联合治疗臂中观察到绝对淋巴细胞计数生物标志物的统计学显著增加，显示了efti的生物活性。
- 基于高度未满足的需求和迄今为止令人鼓舞的结果，预计将于2025年观察到总生存期，未来的发展方向将与监管机构进一步讨论。